Novanta Inc. enters the back half of August with a significant disconnect: shorts are sitting near 14% of the float while the stock has dropped nearly 13% in a single week, yet the borrow market shows no signs of a squeeze building.
The week's move is the central story. NOVT fell 12.8% to $145.24, erasing almost all of its year-to-date gains. That's a sharp drop without an obvious single catalyst, and it doesn't stand alone — close peers COHR and FLEX fell 11% and 12% respectively on the week, and AEVA dropped more than 21%. The precision motion and electronics equipment complex has clearly been hit by a broader selloff, suggesting macro or sector rotation rather than a Novanta-specific event. Next earnings aren't until November 3, so there's no imminent print to re-anchor the story.
Short interest is substantial but not accelerating into the decline. At 14.4% of the free float — roughly 5.16 million shares — NOVT carries one of the heavier short loads in its peer group. Over the past week, short interest barely moved, edging down less than 1%. Bears haven't aggressively added into the weakness. The ORTEX short score of 73 reflects the elevated position, but the borrow market undercuts any squeeze narrative: availability runs at 181% of outstanding short interest, meaning lenders hold nearly twice as many shares available as are currently borrowed. Cost to borrow is modest at 0.53%, down about 45 basis points on the week. The lending market is comfortable, not strained.
Options positioning tells a similar story of entrenched rather than escalating caution. The put/call ratio runs at 2.32 — heavily skewed toward puts in absolute terms, but actually slightly softer than its 20-day average of 2.37. The z-score of -0.44 places this week's reading just below that average, suggesting options traders haven't added meaningful new downside hedges despite the sharp price decline. The 52-week range on the PCR (0.25 to 5.27) highlights just how wide sentiment can swing on this name; right now it's firmly in bearish territory but not at an extreme.
The Street was cautiously optimistic coming into this week, and that picture hasn't updated in real time. Baird lifted its target to $173 in May following a March upgrade to Outperform, and the consensus mean target sits around $194 — implying roughly 34% upside from current levels. With the stock now trading at $145 and a P/E near 34x, the valuation has de-rated meaningfully from levels that already looked stretched. The ORTEX short score rank of 2 and a days-to-cover of over 13 days (per FINRA data) underline how large the short position is relative to average trading volume — a long unwind could take weeks if demand for borrows rises. That said, T. Rowe Price added nearly 951,000 shares in Q2, a material accumulation that signals at least one large institutional holder saw value earlier in the summer.
CEO Matthijs Glastra sold approximately $1.05 million in shares on July 2, spread across several tranches at prices between $160 and $164. Those sales came well above current levels and follow a similar cluster of sales in June. Taken together, the CEO liquidated roughly $1.6 million over June and July — not large enough to alter the thesis on its own, but worth noting given the subsequent price decline.
What to watch next: whether the sharp price decline draws short covering from the 14% short base — given the 13-day days-to-cover and ample availability, the pace of any unwind will be the clearest signal of how bears are reassessing the risk/reward ahead of the November earnings date.
See the live data behind this article on ORTEX.
Open NOVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
